BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
341.80
+23.07 (7.24%)
At close: Sep 5, 2025, 4:00 PM
342.03
+0.23 (0.07%)
After-hours: Sep 5, 2025, 7:53 PM EDT
BeOne Medicines AG Stock Forecast
Stock Price Forecast
The 9 analysts that cover BeOne Medicines AG stock have a consensus rating of "Strong Buy" and an average price target of $335.78, which forecasts a -1.76% decrease in the stock price over the next year. The lowest target is $311 and the highest is $365.
Price Target: $335.78 (-1.76%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 7, 2025.
Analyst Ratings
The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 5 | 7 | 7 | 7 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $349 → $364 | Buy | Maintains | $349 → $364 | +6.50% | Aug 7, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $350 → $365 | Strong Buy | Maintains | $350 → $365 | +6.79% | Aug 7, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $321 → $345 | Buy | Maintains | $321 → $345 | +0.94% | Jul 17, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $311 → $349 | Buy | Maintains | $311 → $349 | +2.11% | Jul 16, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $313 → $330 | Buy | Maintains | $313 → $330 | -3.45% | Jun 27, 2025 |
Financial Forecast
Revenue This Year
37.17B
from 3.81B
Increased by 875.58%
Revenue Next Year
44.97B
from 37.17B
Increased by 20.99%
EPS This Year
0.78
from -6.12
EPS Next Year
2.68
from 0.78
Increased by 243.56%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 40.0B | 48.9B | |||
| Avg | 37.2B | 45.0B | |||
| Low | 35.1B | 41.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 949.0% | 31.6% | |||
| Avg | 875.6% | 21.0% | |||
| Low | 822.3% | 11.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.54 | 3.94 | |||
| Avg | 0.78 | 2.68 | |||
| Low | 0.21 | 1.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 404.1% | |||
| Avg | - | 243.6% | |||
| Low | - | 91.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.